Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Shock,Hemorrhagic Clear all
Completed Phase 2 Interventional

A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma

NCT00081809
View directory record Official record
Conditions
Lymphoma, Follicular, Lymphoma, Small Lymphocytic
Interventions
autologous human tumor-derived HSPPC-96
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jul 21, 2026, 11:42 AM EDT
Completed No phase listed Observational

Vasopressin Deficiency in Hemorrhagic Shock

NCT01107314
View directory record Official record
Conditions
Body Response to Trauma
Interventions
Phlebotomy
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 98 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Jul 21, 2026, 11:42 AM EDT
Terminated Not applicable Interventional Results available

Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer

NCT02376933
View directory record Official record
Conditions
Metastatic Cancers, Multiple Myeloma, Vertebral Fracture
Interventions
Vertebroplasty, Radiotherapy
Procedure · Radiation
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 3 Interventional

A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

NCT00546780
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Tanespimycin, Bortezomib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
18
States / cities
Bakersfield, California • La Jolla, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Jul 21, 2026, 11:42 AM EDT
Not listed Phase 3 Interventional

Safety and Efficacy of PolyHeme(R) in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Pre-Hospital Setting

NCT00076648
View directory record Official record
Conditions
Hemorrhagic Shock
Interventions
Poly SFH-P Injection
Drug
Lead sponsor
Northfield Laboratories
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
32
States / cities
San Diego, California • Denver, Colorado • Newark, Delaware + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2006 · Synced Jul 21, 2026, 11:42 AM EDT
Withdrawn No phase listed Observational

Serum Vasopressin Levels and Severe Hemorrhagic Shock

NCT01676454
View directory record Official record
Conditions
Injury
Interventions
Not listed
Lead sponsor
Poudre Valley Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Not applicable Interventional Results available

Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma

NCT01536496
View directory record Official record
Conditions
Acute Coagulopathy
Interventions
Blood product transfusion based on conventional coagulation tests., Blood product transfusion based on rapid thrombelastography (r-TEG) results.
Biological
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine

NCT00473135
View directory record Official record
Conditions
Dengue
Interventions
rDEN1delta30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Jul 21, 2026, 11:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume

NCT01935427
View directory record Official record
Conditions
Hemorrhage
Interventions
Not listed
Lead sponsor
Flashback Technologies
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Cold Stored Platelet in Hemorrhagic Shock

NCT04667468
View directory record Official record
Conditions
Trauma, Hemorrhage
Interventions
Cold Stored Platelets (CSP), Standard Care
Biological
Lead sponsor
Jason Sperry
Other
Eligibility
15 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Jul 21, 2026, 11:42 AM EDT
Terminated No phase listed Observational

Hypertonic Modulation of Inflammation Following Injury

NCT00750997
View directory record Official record
Conditions
Hemorrhagic Shock, Traumatic Brain Injury
Interventions
hypertonic saline
Drug
Lead sponsor
University of Washington
Other
Eligibility
15 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Jul 21, 2026, 11:42 AM EDT
Terminated No phase listed Observational

A 48 Subject Study Using Non-invasive Multi-Technology Measurements for Early Detection of Ongoing Hemorrhage

NCT04814810
View directory record Official record
Conditions
Occult Bleeding, Hemorrhage, Hemorrhagic Shock
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Jul 21, 2026, 11:42 AM EDT
Not listed No phase listed Observational

Blood Transfusion by Boston MedFlight Registry

NCT04610814
View directory record Official record
Conditions
Hemorrhagic Shock
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Jul 21, 2026, 11:42 AM EDT
Terminated No phase listed Observational

The Use of Tissue Oxygen Monitoring in Critically Injured Patients

NCT00328341
View directory record Official record
Conditions
Traumatic Brain Injury, Hemorrhagic Shock, Trauma
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Not applicable Interventional Results available

Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy

NCT01239680
View directory record Official record
Conditions
Hemorrhagic Shock
Interventions
Glutamine, Ringer's Lactate, Placebo (for Glutamine)
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
21 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine

NCT01072786
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV Vaccine-Admixture 1, TetraVax-DV Vaccine-Admixture 2, TetraVax-DV Vaccine-Admixture 3, TetraVax-DV Vaccine-Admixture 4, Placebo, TetraVax-DV Vaccine-Admixture 5
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 21, 2026, 11:42 AM EDT
Recruiting Phase 3 Interventional

Trauma Resuscitation With Low-Titer Group O Whole Blood or Products

NCT05638581
View directory record Official record
Conditions
Wounds and Injuries, Shock, Hemorrhagic
Interventions
LTOWB, Components
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
15 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

NCT04975555
View directory record Official record
Conditions
Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia
Interventions
Siltuximab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma

NCT01411852
View directory record Official record
Conditions
Blunt Trauma, Penetrating Wound, Hemorrhagic Shock
Interventions
0.9% Sodium Chloride 250 mL bolus, 0.9% Sodium Chloride 2000 mL bolus
Drug
Lead sponsor
University of Washington
Other
Eligibility
15 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Birmingham, Alabama • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Jul 21, 2026, 11:42 AM EDT
Not listed Phase 2 Interventional

Polydatin Injectable (HW6) for Shock Treatment

NCT01780129
View directory record Official record
Conditions
Shock, Hemorrhagic, Shock, Traumatic, Shock, Septic
Interventions
Polydatin Injectable
Drug
Lead sponsor
Neptunus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults

NCT00094705
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN2/4delta30(ME) Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2008 · Synced Jul 21, 2026, 11:42 AM EDT
Recruiting Phase 2 Interventional

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

NCT07657312
View directory record Official record
Conditions
Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Naresh Bumma
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 2Phase 3 Interventional

A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma

NCT00514371
View directory record Official record
Conditions
Multiple Myeloma
Interventions
tanespimycin, Bortezomib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
11
States / cities
Berkeley, California • San Francisco, California • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Jul 21, 2026, 11:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults

NCT00270699
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN4delta30-200,201, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 21, 2026, 11:42 AM EDT